| First Author | Nurden AT | Year | 2011 |
| Journal | Blood | Volume | 118 |
| Issue | 23 | Pages | 5996-6005 |
| PubMed ID | 21917754 | Mgi Jnum | J:179110 |
| Mgi Id | MGI:5301075 | Doi | 10.1182/blood-2011-07-365635 |
| Citation | Nurden AT, et al. (2011) Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118(23):5996-6005 |
| abstractText | Characterized by mucocutaneous bleeding arising from a lack of platelet aggregation to physiologic stimuli, Glanzmann thrombasthenia (GT) is the archetype-inherited disorder of platelets. Transmitted by autosomal recessive inheritance, platelets in GT have quantitative or qualitative deficiencies of the fibrinogen receptor, alphaIIbbeta3, an integrin coded by the ITGA2B and ITGB3 genes. Despite advances in our understanding of the disease, extensive phenotypic variability with respect to severity and intensity of bleeding remains poorly understood. Importantly, genetic defects of ITGB3 also potentially affect other tissues, for beta3 has a wide tissue distribution when present as alphavbeta3 (the vitronectin receptor). We now look at the repertoire of ITGA2B and ITGB3 gene defects, reexamine the relationship between phenotype and genotype, and review integrin structure in the many variant forms. Evidence for modifications in platelet production is assessed, as is the multifactorial etiology of the clinical expression of the disease. Reports of cardiovascular disease and deep vein thrombosis, cancer, brain disease, bone disorders, and pregnancy defects in GT are discussed in the context of the results obtained for mouse models where nonhemostatic defects of beta3-deficiency or nonfunction are being increasingly described. |
